Novo Nordisk buys back DKK 9.94B in shares
Treasury holdings stood at 49,419,876 B shares, or 1.1% of Novo Nordisk's share capital, after the reported transactions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Novo Nordisk A/S reported additional B-share purchases under a programme allowing repurchases of up to DKK 11,200,000,010.45 from May 6, 2026, through February 1, 2027. The programme is part of an overall share repurchase programme of up to DKK 15 billion over the 12-month period beginning February 4, 2026.
Cumulative purchases under the programme initiated May 6 were 20,620,000 B shares, with a transaction value of DKK 6,139,842,042. Following the reported transactions, Novo Nordisk held 49,419,876 B shares as treasury shares, equal to 1.1% of its share capital. Across the overall programme, purchases since February 4 were reported at DKK 9,939,842,031 as of September 25, 2026, at an average price of DKK 280.95 per B share. The total A and B share count, including treasury shares, was 4,465,000,000.
Key Figures
Key Terms
Safe Harbour Rules regulatory
average purchase price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
September 28, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 28 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 21 September, the following transactions have been made:
Number of B shares |
Average purchase price |
Transaction value, DKK | |
| Accumulated, last announcement |
19,415,000 |
5,829,922,946 | |
| 21 September 2026 | 250,000 | 267.41 | 66,853,084 |
| 22 September 2026 | 250,000 | 258.30 | 64,575,341 |
| 23 September 2026 | 220,000 | 256.17 | 56,357,077 |
| 24 September 2026 | 240,000 | 250.42 | 60,101,974 |
| 25 September 2026 | 245,000 | 253.19 | 62,031,620 |
| Accumulated under the programme |
20,620,000 |
6,139,842,042 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 49,419,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 25 September 2026, Novo Nordisk has since 4 February 2026 repurchased a total 3 5,379,179 B shares at an average share price of DKK 280.95 per B share equal to a transaction value of DKK 9,939,842,031.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Novo Nordisk Media: | |
| Ambre James-Brown | Liz Skrbkova (US) |
| +45 3079 9289 | +1 609 917 0632 |
| globalmedia@novonordisk.com |
USMediaRelations@novonordisk.com |
| Novo Nordisk Investors: | |
| Michael Novod | Sina Meyer |
| +45 3075 6050 | +45 3079 6656 |
nvno@novonordisk.com |
azey@novonordisk.com |
| Christoffer Togo Solgaard-Tullin | |
| +45 3079 1471 | |
| cftu@novonordisk.com | |
| Ida Schaap Melvold | Mads Berner Bruun |
| +45 3077 5649 | +45 3075 2936 |
| idmg@novonordisk.com | mbbz@novonordisk.com |
Frederik Taylor Pitter (US) |
Alex Bruce (US) |
| +1 609 613 0568 | +1 640 230 0276 |
fptr@novonordisk.com |
axeu@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 58 / 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: September 28, 2026 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |